Publications by authors named "Kevin Fain"

Claim this Profile
E
Evaluating the Revised National Institutes of Health Clinical Trial Definition Impact on Recruitment Progress.
Eugene I Kane, Gail L Daumit, Kevin M Fain, Roberta W Scherer, Emma Elizabeth McGinty

Res Eval· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National Institute of Mental Health Recruitment Monitoring Policy and Clinical Trial Impact.
Eugene I Kane, Gail L Daumit, Kevin M Fain, Brendan Saloner, Roberta W Scherer

Contemp Clin Trials· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential benefits and burdens of National Institutes of Health and National Institute of Mental Health clinical trial policies.
Eugene I Kane, Gail L Daumit, Kevin M Fain, Roberta W Scherer, Emma Elizabeth McGinty

Contemp Clin Trials· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Race and ethnicity reporting for clinical trials in ClinicalTrials.gov and publications.
Kevin M Fain, Julianne T Nelson, Tony Tse, Rebecca J Williams

Contemp Clin Trials· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
10-Year Update on Study Results Submitted to ClinicalTrials.gov.
Deborah A Zarin, Kevin M Fain, Heather D Dobbins, Tony Tse, Rebecca J Williams

N Engl J Med· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results Reporting for Trials With the Same Sponsor, Drug, and Condition in ClinicalTrials.gov and Peer-Reviewed Publications.
Kevin M Fain, Thiyagu Rajakannan, Tony Tse, Rebecca J Williams, Deborah A Zarin

JAMA Intern Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aversive and Appetitive Learning in Larvae: A Simple and Powerful Suite of Laboratory Modules for Classroom or Open-ended Research Projects.
Austin Pavin, Kevin Fain, Allison DeHart, Divya Sitaraman

J Undergrad Neurosci Educ· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider.
Tony Tse, Kevin M Fain, Deborah A Zarin

BMJ· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inappropriate Fentanyl Prescribing Among Nursing Home Residents in the United States.
Kevin M Fain, Carlos Castillo-Salgado, David D Dore, Jodi B Segal, Andrew R Zullo

J Am Med Dir Assoc· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency and Predictors of Analgesic Prescribing in U.S. Nursing Home Residents with Persistent Pain.
Kevin M Fain, G Caleb Alexander, David D Dore, Jodi B Segal, Andrew R Zullo

J Am Geriatr Soc· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence selection for a prescription drug's benefit-harm assessment: challenges and recommendations.
Kevin M Fain, Tsung Yu, Tianjing Li, Cynthia M Boyd, Sonal Singh

J Clin Epidemiol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of surrogate outcomes in US FDA drug approvals, 2003-2012: a survey.
Tsung Yu, Yea-Jen Hsu, Kevin M Fain, Cynthia M Boyd, Janet T Holbrook

BMJ Open· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Markers of Impaired Decision Making in Nursing Home Residents: Assessment by Nursing Home Staff in a Population-Based Study.
Kevin M Fain, Paul B Rosenberg, Sandrine Pirard, Olivera Bogunovic, Adam P Spira

J Am Med Dir Assoc· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disposing of medicines safely.
Kevin M Fain, G Caleb Alexander

Am J Public Health· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits and harms of roflumilast in moderate to severe COPD.
Tsung Yu, Kevin Fain, Cynthia M Boyd, Sonal Singh, Carlos O Weiss

Thorax· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply letter: are FDA prescription drug safety plans working? A case study of isotretinoin.
Kevin Fain, G Caleb Alexander

Pharmacoepidemiol Drug Saf· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mind the gap: understanding the effects of pharmaceutical direct-to-consumer advertising.
Kevin M Fain, G Caleb Alexander

Med Care· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are Food and Drug Administration prescription drug safety plans working? A case study of isotretinoin.
Kevin Fain, G Caleb Alexander

Pharmacoepidemiol Drug Saf· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug postmarketing studies--reply.
Kevin Fain, G Caleb Alexander

JAMA· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Food and Drug Administration Amendments Act and postmarketing commitments.
Kevin Fain, Matthew Daubresse, G Caleb Alexander

JAMA· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis